

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

VOLUNTARY ANNOUNCEMENT

UPDATE ON STATUS OF EAL[®]

AND

APPROVAL FOR CLINICAL TRANSLATIONAL APPLICATION OF ATL

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Immunotech Biopharm Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

STATUS OF EAL[®]

Reference is made to the inside information announcement published by the Company on 28 April 2026.

The Group is currently liaising with CDE on the protocol of the confirmatory clinical trial, and shall commence the confirmatory clinical trial upon finalisation of the protocol. Based on past experience, the Company expects to re-submit of the new drug use application for EAL[®] for the prevention of postoperative recurrence of liver cancer in about 39 months from commencement of the confirmatory clinical trial.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The Company cannot guarantee that the Group will be able to obtain further approval for, or ultimately market, EAL[®], successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

APPROVAL FOR CLINICAL TRANSLATIONAL APPLICATION OF THE NEW INNOVATIVE BIOMEDICAL TECHNOLOGY OF ATL

The Company has developed Activated T Lymphocytes (“ATL”). ATL is extracted and prepared from the patient’s own peripheral blood mononuclear cells, and possesses both the potent anti-tumor property of T-lymphocytes and the non-Major Histocompatibility Complex (MHC)-restricted tumor killing property of Natural Killer (NK) cells.

The Group has received conditional approval from the Medical Product Administration of Lecheng, Hainan (海南省樂城醫療藥品監管局) in September 2025 for clinical translational application of ATL for the prevention of postoperative recurrence of liver cancer at Hainan Bo’ao Lecheng International Medical Tourism Pilot Zone (海南博鰲樂城國際醫療旅遊先行區), and has initiated commercialisation process in April 2026. The Group has also received approval for clinical use of ATL in Beidaihe Life and Health Industry Innovation Demonstration Zone (北戴河生命健康產業創新示範區) in April 2026, and expects to initiate commercialisation in June 2026. As at the date of this announcement, ATL therapy has been applied to two patients, and three infusions of ATL have been completed.

The Company expects to generate revenue from the commercialisation of ATL, and shall continue promoting translational application of ATL.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 3 June 2026

As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Mr Yang Fan, Mr Wang Ruihua, Mr Wang Donghu, Mr Yang Xin, Mr Liu Rui and Mr Cao Ran as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit, Ms Peng Sujiu and Mr Zhang Guoguang as independent non-executive Directors.